Zhi Tong Cai Jing·2026-03-18 02:17Core Viewpoint - Rongchang Biopharma (09995) has seen a significant stock price increase, attributed to positive developments in its product pipeline and strong financial performance [1] Group 1: Stock Performance - Rongchang Biopharma's stock rose nearly 8%, with a current price of 96.8 HKD and a trading volume of 238 million HKD [1] Group 2: Industry Developments - The 2026 European Association of Urology (EAU) annual meeting is taking place in London from March 13 to 16, showcasing innovative applications of HER2-targeted antibody-drug conjugate (ADC) Vidisitamab in the treatment of urothelial carcinoma [1] - Multiple cutting-edge research results from China were presented, covering the entire disease spectrum from early to late stages, including bladder cancer and upper urinary tract urothelial carcinoma, providing strong new evidence for precision and organ-preserving treatments [1] Group 3: Financial Performance - Rongchang Biopharma reported a revenue of 3.251 billion RMB, a year-on-year increase of 89.36% [1] - The company achieved a net profit attributable to shareholders of 709 million RMB, marking a turnaround from losses [1] - Revenue growth is primarily driven by increased sales of injectable Taitasip and injectable Vidisitamab, along with significant technology licensing income from granting Vor Biopharma Inc. exclusive global development and commercialization rights outside Greater China [1]